• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

DAPT guided by platelet function tests or genotyping after PCI: pros and cons.

作者信息

Angiolillo Dominick J, Galli Mattia, Landi Antonio, Valgimigli Marco

机构信息

Division of Cardiology, University of Florida College of Medicine - Jacksonville, Jacksonville, FL, USA.

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.

出版信息

EuroIntervention. 2023 Sep 18;19(7):546-548. doi: 10.4244/EIJ-E-23-00022.

DOI:10.4244/EIJ-E-23-00022
PMID:37720965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10493773/
Abstract
摘要

相似文献

1
DAPT guided by platelet function tests or genotyping after PCI: pros and cons.PCI术后血小板功能检测或基因分型指导下的双联抗血小板治疗：利弊
EuroIntervention. 2023 Sep 18;19(7):546-548. doi: 10.4244/EIJ-E-23-00022.
2
Antiplatelet monotherapy after DAPT: is clopidogrel the new standard? Pros and cons.双联抗血小板治疗后使用抗血小板单药治疗：氯吡格雷是新标准吗？利弊分析。
EuroIntervention. 2024 Jun 17;20(12):e737-e739. doi: 10.4244/EIJ-E-24-00009.
3
Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry - Informing optimal antiplatelet strategies.经皮冠状动脉介入治疗（PCI）后的精准抗血小板治疗（Precision PCI）注册研究——为优化抗血小板策略提供信息。
Clin Transl Sci. 2024 Aug;17(8):e70004. doi: 10.1111/cts.70004.
4
Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.在不受限制的经皮冠状动脉介入治疗人群中使用双联抗血小板治疗评分预测缺血和出血事件。
Circ Cardiovasc Interv. 2018 Oct;11(10):e006853. doi: 10.1161/CIRCINTERVENTIONS.118.006853.
5
Aspirin should be stopped at day 0 after PCI: pros and cons.经皮冠状动脉介入治疗（PCI）术后第0天应停用阿司匹林：利弊分析
EuroIntervention. 2023 Apr 3;18(16):e1304-e1306. doi: 10.4244/EIJ-E-23-00001.
6
Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.经皮冠状动脉介入治疗术后患者的基因分型、血小板活化与心血管结局：氯吡格雷抵抗难题的两个方面
Cardiology. 2017;137(2):104-113. doi: 10.1159/000457947. Epub 2017 Mar 22.
7
Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.血小板功能检测指导抗血小板治疗降低中国 ST 段抬高型心肌梗死经皮冠状动脉介入治疗患者的心血管事件：PATROL 研究。
Catheter Cardiovasc Interv. 2020 Feb;95 Suppl 1:598-605. doi: 10.1002/ccd.28712. Epub 2020 Jan 20.
8
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.更新的血小板功能和基因检测指导经皮冠状动脉介入治疗中 P2Y 受体抑制剂治疗的专家共识声明。
JACC Cardiovasc Interv. 2019 Aug 26;12(16):1521-1537. doi: 10.1016/j.jcin.2019.03.034. Epub 2019 Jun 12.
9
Smoking and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients: a substudy from the randomized TROPICAL-ACS trial.急性冠状动脉综合征患者抗血小板治疗降级指导后吸烟与结局的关系：来自随机 TROPICAL-ACS 试验的亚研究。
Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):372-381. doi: 10.1093/ehjcvp/pvz084.
10
Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.比较血管内超声或血管造影指导下急性冠脉综合征患者药物洗脱支架植入术后 1 个月与 12 个月双联抗血小板治疗：前瞻性、多中心、随机、对照 IVUS-ACS 和 ULTIMATE-DAPT 试验的原理和设计。
Am Heart J. 2021 Jun;236:49-58. doi: 10.1016/j.ahj.2021.02.014. Epub 2021 Feb 20.

本文引用的文献

1
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC).已确诊冠心病患者抗血栓治疗策略12个月内及以后的疗效与安全性：欧洲经皮心血管介入协会（EAPCI）、欧洲急性心血管护理协会（ACVC）和欧洲预防心脏病学协会（EAPC）2022年联合临床共识声明的两项配套网状Meta分析
Eur Heart J Cardiovasc Pharmacother. 2023 Apr 10;9(3):271-290. doi: 10.1093/ehjcvp/pvad016.
2
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis.高出血风险患者接受复杂经皮冠状动脉介入治疗后抗血小板治疗的持续时间：MASTER DAPT试验的亚组分析
Eur Heart J. 2022 Sep 1;43(33):3100-3114. doi: 10.1093/eurheartj/ehac284.
3
Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention.血小板功能及基因检测在接受经皮冠状动脉介入治疗患者中的作用
Trends Cardiovasc Med. 2023 Apr;33(3):133-138. doi: 10.1016/j.tcm.2021.12.007. Epub 2021 Dec 20.
4
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.比较指导下与强效 P2Y12 抑制剂治疗急性冠脉综合征的效果：来自 15 项随机试验的 61898 例患者的网络荟萃分析。
Eur Heart J. 2022 Mar 7;43(10):959-967. doi: 10.1093/eurheartj/ehab836.
5
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.高出血风险患者经皮冠状动脉介入治疗（PCI）后的双联抗血小板治疗。
N Engl J Med. 2021 Oct 28;385(18):1643-1655. doi: 10.1056/NEJMoa2108749. Epub 2021 Aug 28.
6
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials.冠状动脉血运重建术后P2Y12抑制剂单药治疗或双联抗血小板治疗：随机对照试验的个体患者水平荟萃分析
BMJ. 2021 Jun 16;373:n1332. doi: 10.1136/bmj.n1332.
7
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.经皮冠状动脉介入治疗患者中接受指导与标准抗血小板治疗的比较：系统评价和荟萃分析。
Lancet. 2021 Apr 17;397(10283):1470-1483. doi: 10.1016/S0140-6736(21)00533-X.
8
Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y Inhibitor Therapy: A Meta-Analysis.CYP2C19 基因型对口服 P2Y 抑制剂治疗期间缺血结局的影响：一项荟萃分析。
JACC Cardiovasc Interv. 2021 Apr 12;14(7):739-750. doi: 10.1016/j.jcin.2021.01.024. Epub 2021 Mar 17.
9
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.更新的血小板功能和基因检测指导经皮冠状动脉介入治疗中 P2Y 受体抑制剂治疗的专家共识声明。
JACC Cardiovasc Interv. 2019 Aug 26;12(16):1521-1537. doi: 10.1016/j.jcin.2019.03.034. Epub 2019 Jun 12.
10
Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis.基于血小板反应性检测的强化抗血小板治疗对经皮冠状动脉介入治疗后患者的疗效和安全性：系统评价和荟萃分析。
Int J Cardiol. 2013 Sep 1;167(5):2140-8. doi: 10.1016/j.ijcard.2012.05.100. Epub 2012 Jun 15.